5 Endocrinology Headlines You Missed in July 2026

July 2026 was relatively quiet for endocrinology. The US Food and Drug Administration (FDA) had no significant approvals, instead accepting 2 exciting New Drug Applications (NDAs) for the treatment of hypocalcemia and acromegaly, respectively. Additionally, key trials for type 1 diabetes (T1D), type 2 diabetes (T2D), and weight maintenance following GLP-1 RA discontinuation had topline results read out over the course of the month, moving major candidates like encaleret and tegoprubart further down the treatment pipeline towards an FDA decision.